The Association Between Short-Acting β
Asthma management
Asthma outcomes
Over-the-counter medication
Prescription patterns
Short-acting β2-agonists
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
04 Feb 2024
04 Feb 2024
Historique:
received:
03
08
2023
accepted:
20
11
2023
medline:
4
2
2024
pubmed:
4
2
2024
entrez:
4
2
2024
Statut:
aheadofprint
Résumé
In Australia, short-acting β This was a cross-sectional study, using data derived from primary care electronic medical records (EMRs) and patient completed questionnaires within Optimum Patient Care Research Database Australia (OPCRDA). A total of 720 individuals aged ≥ 12 years with an asthma diagnosis in their EMRs and receiving asthma therapy were included. The annual number of SABA inhalers authorised on prescription, acquired OTC and reported, and the association with self-reported exacerbations and asthma control were investigated. 92.9% (n = 380/409) of individuals issued with SABA prescription were authorised ≥ 3 inhalers annually, although this differed from self-reported usage. Of individuals reporting SABA use (n = 546) in the last 12 months, 37.0% reported using ≥ 3 inhalers. These patients who reported SABA overuse experienced 2.52 (95% confidence interval [CI] 1.73-3.70) times more severe exacerbations and were 4.51 times (95% CI 3.13-6.55) more likely to have poor asthma control than those who reported using 1-2 SABA inhalers. Patients who did not receive SABA on prescription (43.2%; n = 311/720) also experienced 2.71 (95% CI 1.07-7.26) times more severe exacerbations than those prescribed 1-2 inhalers. Of these patients, 38.9% reported using OTC SABA and other prescription medications, 26.4% reported using SABA OTC as their only asthma medication, 13.2% were prescribed other therapies but not SABA OTC and 14.5% were not using any medication. Both self-reported SABA overuse and zero SABA prescriptions were associated with poor asthma outcomes. The disconnect between prescribing authorisation, OTC availability and actual use, make it difficult for clinicians to quantify SABA use.
Identifiants
pubmed: 38310584
doi: 10.1007/s12325-023-02746-0
pii: 10.1007/s12325-023-02746-0
doi:
Types de publication
Journal Article
Langues
eng
Investigateurs
Rob Campbell
(R)
Ying Liu
(Y)
Nicole O'Sullivan
(N)
Ondrej Rejda
(O)
Lisa Sugg
(L)
Steph James
(S)
Kiran Dhillon
(K)
Sophie Jones
(S)
Informations de copyright
© 2024. The Author(s).
Références
Crooks MG, Faruqi S. It is time to end our love affair with short-acting β(2)-agonists in asthma. ERJ Open Res. 2022;8:00353–2022.
doi: 10.1183/23120541.00353-2022
pubmed: 36267894
pmcid: 9574554
Martin MJ, Harrison TW. Is it time to move away from short-acting beta-agonists in asthma management? Eur Respir J. 2019;53:1802223.
doi: 10.1183/13993003.02223-2018
pubmed: 30948504
Blakeston S, Harper G, Zabala MJ. Identifying the drivers of patients’ reliance on short-acting β2-agonists in asthma. J Asthma. 2021;58:1094–101.
doi: 10.1080/02770903.2020.1761382
pubmed: 32469667
Bloom CI, Cabrera C, Arnetorp S, Coulton K, Nan C, van der Valk RJP, et al. Asthma-related health outcomes associated with short-acting β(2)-agonist inhaler use: an observational UK study as part of the SABINA Global Program. Adv Ther. 2020;37:4190–208.
doi: 10.1007/s12325-020-01444-5
pubmed: 32720299
Quint JK, Arnetorp S, Kocks JWH, Kupczyk M, Nuevo J, Plaza V, et al. Short-acting Beta-2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. J Allergy Clin Immunol Pract. 2022;S2213–2198(22):00285–9.
Bateman ED, Price DB, Wang H-C, Khattab A, Schonffeldt P, Catanzariti A, et al. Short-acting β(2)-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2022;59:2101402.
doi: 10.1183/13993003.01402-2021
pubmed: 34561293
pmcid: 9068976
FitzGerald JM, Tavakoli H, Lynd LD, Al Efraij K, Sadatsafavi M. The impact of inappropriate use of short acting beta agonists in asthma. Respir Med. 2017;131:135–40.
doi: 10.1016/j.rmed.2017.08.014
pubmed: 28947020
Azzi EA, Kritikos V, Peters MJ, Price DB, Srour P, Cvetkovski B, et al. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta(2) agonists: an Australian community pharmacy-based survey. BMJ Open. 2019;9: e028995.
doi: 10.1136/bmjopen-2019-028995
pubmed: 31412998
pmcid: 6701672
Price D, Wilson AM, Chisholm A, Rigazio A, Burden A, Thomas M, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1–12.
pubmed: 26793004
pmcid: 4708874
Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, Postma DS, et al. Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative. J Allergy Clin Immunol Pract. 2017;5:1015-1024.e8.
doi: 10.1016/j.jaip.2016.11.007
pubmed: 28017629
Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β(2)-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55:1901872.
doi: 10.1183/13993003.01872-2019
pubmed: 31949111
pmcid: 7160635
McKibben S, Bush A, Thomas M, Griffiths C. “Tossing a coin:” defining the excessive use of short-acting beta(2)-agonists in asthma-the views of general practitioners and asthma experts in primary and secondary care. NPJ Prim Care Respir Med. 2018;28:26.
doi: 10.1038/s41533-018-0096-4
pubmed: 30022059
pmcid: 6052065
Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling ZJJ, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204.
doi: 10.2147/JAA.S176026
pubmed: 30214247
pmcid: 6121746
Soremekun S, Heaney L, Skinner D, Bulathsinhala L, Carter V, Chaudhry I, et al. Asthma exacerbations are associated with a decline in lung function: a longitudinal population based study. Thorax. 2023;78:643–52 (Epub ahdead of print).
doi: 10.1136/thorax-2021-217032
pubmed: 35922128
National Asthma Council. Australian Asthma Handbook Version 2.2 [Internet]. 13th ed. 2022. https://www.asthmahandbook.org.au/ . Accessed 9 Dec 2022.
Azzi E, Kritikos V, Peters M, Price D, Cvetkovski B, Alphonse PS, et al. Perceptions, attitudes, and behaviors of short-acting beta(2) agonist users: an Australian cross-sectional community pharmacy-based study. J Asthma. 2022;59:178–88.
doi: 10.1080/02770903.2020.1841223
pubmed: 33086885
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2023. 2023; https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf . Accessed 9 Dec 2022.
Price D, Hancock K, Doan J, Taher SW, Muhwa CJ, Farouk H, et al. Short-acting β(2)-agonist prescription patterns for asthma management in the SABINA III primary care cohort. NPJ Prim Care Respir Med. 2022;32:37.
doi: 10.1038/s41533-022-00295-7
pubmed: 36175556
pmcid: 9522811
Domingo C, Singh D. The changing asthma management landscape and need for appropriate SABA prescription. Adv Ther. 2023;40:1301–16.
doi: 10.1007/s12325-022-02410-z
pubmed: 36715896
pmcid: 10070225
Sawyer SM, Fardy HJ. Bridging the gap between doctors’ and patients’ expectations of asthma management. J Asthma. 2003;40:131–8.
doi: 10.1081/JAS-120017983
pubmed: 12765314
Chung LP, Johnson P, Summers Q. Models of care for severe asthma: the role of primary care. Med J Aust. 2018;209:S34-40.
doi: 10.5694/mja18.00119
pubmed: 30453871
Loh ZC, Hussain R, Balan S, Saini B, Muneswarao J, Ong SC, et al. Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β2-agonists: a systematic review. PLoS One. 2023;18: e0283876.
doi: 10.1371/journal.pone.0283876
pubmed: 37079594
pmcid: 10118161
Ampon RD, Reddel HK, Correll PK, Poulos LM, Marks GB. Cost is a major barrier to the use of inhaled corticosteroids for obstructive lung disease. Med J Aust. 2009;191:319–23.
doi: 10.5694/j.1326-5377.2009.tb02815.x
pubmed: 19769554
Laba T-L, Jan S, Zwar NA, Roughead E, Marks GB, Flynn AW, et al. Cost-related underuse of medicines for asthma-opportunities for improving adherence. J Allergy Clin Immunol Pract. 2019;7:2298-2306.e12.
doi: 10.1016/j.jaip.2019.03.024
pubmed: 30928659
O’Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. Asthma progression and mortality: the role of inhaled corticosteroids. Eur Respir J. 2019;54:1900491.
doi: 10.1183/13993003.00491-2019
pubmed: 31048346
pmcid: 6637285
Reddel HK, Cooper, S, Guevara-Rattray E, Ampon RD, Marks GB. Asthma control in Australia 1990–2011 21 years since the introduction of asthma managment guidelines—where are we now? [Internet]. Woolcock Institute of Medical Research; 2013. https://www.woolcock.org.au/pdf/downloads/Asthma-control-in-Australia-1990-2011.pdf . Accessed 13 Jul 2022.
Department of Health SG of V. Epidemic thunderstorm asthma [Internet]. Epidemic thunderstorm asthma. 2022. https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/thunderstorm-asthma . Accessed 11 Nov 2022.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention [Internet]. 2022. https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf . Accessed 19 Oct 2022.
Canonica GW, Paggiaro P, Blasi F, Musarra A, Richeldi L, Rossi A, et al. Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies. Ther Adv Respir Dis. 2021;15:17534666211042534.
doi: 10.1177/17534666211042534
pubmed: 34587829
pmcid: 8488406
Putman B, Coucke L, Vanoverschelde A, Mehuys E, Lahousse L. Community pharmacist counseling improves adherence and asthma control: a nationwide study. BMC Health Serv Res. 2022;22:112.
doi: 10.1186/s12913-022-07518-0
pubmed: 35081939
pmcid: 8790878
Bridgeman MB, Wilken LA. Essential role of pharmacists in asthma care and management. J Pharm Pract. 2021;34:149–62.
doi: 10.1177/0897190020927274
pubmed: 32495701
National Asthma Council. Australian Asthma Handbook [Internet]. Managing Asthma in Adults. (2022). Available from: https://web.archive.org/web/20171129113442/ , http://www.asthmahandbook.org.au/management/adults . Accessed 20 Sept 2022.